ORIC Pharmaceuticals (ORIC) stock price, chart and financials

Price chart

Revenue (trailing twelve months)

—

Revenue (quarter)

—

Revenue growth (year over year)

—

Gross profit (trailing twelve months)

—

Gross margin

—

Net income (trailing twelve months)

—

Net income (quarter)

−$41.5M

Net income growth (year over year)

−14.13%

Net margin

—

Return on equity

−39.80%

EPS (trailing twelve months)

−$1.30

Book value per share

$3.68

P/E (trailing twelve months)

—

Price to book

3.23

Debt to assets

5.79%

Payout ratio

—

Dividend yield

—

Company profile

ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It has a pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. The company has product candidates namely ORIC-944, ORIC-114, and ORIC-533. The Company has as one operating segment, focused on the discovery and development of therapies designed to counter the resistance mechanisms in cancer.

• How do I buy stock in ORIC Pharmaceuticals (ORIC)?

  ORIC trades commission-free with a Light Horse Securities brokerage account — from the mobile app, the web at Light Horse Dashboard, the trading API, or an AI agent connected over MCP. The trade panel on this page places the order once you are signed in.